 Britains GlaxoSmithKline plc LON: GSK announced in a joint statement with the U.S. based Vir Biotechnology Inc NASDAQ: VIR on Wednesday that the U.S. government had agreed to buy about 1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th The number of doses of Sotrovimab ... The post U.S. places a sizable order for GSK-Virs COVID-19 treatment appeared first on Invezz. 